By matching patients with stomach cancer to healthy controls, recording use of proton pump inhibitors (PPIs) and taking into account factors such as age, smoking and obesity, researchers from the Karolinska Institute, among others, have concluded there was no connection between the drugs and stomach cancer.
"This discovery should be a relief for patients who require long-term treatment with proton pump inhibitors and is valuable for healthcare professionals in clinical decision-making," the researchers said in a press release.
The study is published in the journal BMJ.
